Committed to the Future of Antibiotics

22 August 2018

Presenting Research at ACG 2018 on Quality of Life of Patients with Clostridium difficile

The Da Volterra team is thrilled to present a poster at the (...)

17 August 2018

Da Volterra receives new patent for innovative DAV132

The US Patent and Trademark Office has recently granted a new (...)

8 August 2018

Da Volterra Pleased to Sponsor the 6th International C. difficile Symposium September 12-14th

Da Volterra is pleased to be a sponsor of the 6th International (...)

20 July 2018

Tune-in July 24th to C. Diff Spores and More Radio Show to Learn About DAV132 with Our CSO

Da Volterra is looking forward to being on air with the C. Diff (...)

Who we are

Da Volterra:
Committed to the Future of Antibiotics

Da Volterra is a biotechnology company developing a portfolio of unique products in the antibacterial field, with a specific focus on antibiotic resistance.

Our most advanced product is DAV132, developed to prevent the disruption of the intestinal microbiota and prevent Clostridium difficile infections associated with antibiotic use. Discover DAV132 in the video below:

DAV132 has already undergone three phase I clinical trials. It has been developed using in-house expertise on resistant gut microbiomes and proprietary drug delivery technologies. Learn more >

500,000 Americans infected
by Clostridium difficile
each year

Learn more >


Developpeur PHP Drupal